Factors Predicting Prognosis of Epilepsy After Presentation with Seizures
Overview
Affiliations
The objective of this study was to identify the factors, at the time of diagnosis, that determine the prognosis for remission of epilepsy. A prospective community-based cohort study of 792 patients recruited at the time of their first diagnosis of epileptic seizures was undertaken; in those classified 6 months after presentation, the median follow-up period was 7.2 years (quartiles at 6.2 and 8.2 years) after presentation. We analyzed data from 6 months after the first identified seizure, which prompted the diagnosis of epilepsy, to allow us to factor in those aspects contingent on a diagnostic assessment Baseline clinical and demographic data were analyzed using the Cox proportional hazards regression model with remission of epilepsy for 1, 2, 3, and 5 years as outcome measures. The dominant clinical feature predicting remission was the number of seizures in the 6-month diagnostic assessment period. Thus, the chance of entering 1 year of remission by 6 years for a patient who had 2 seizures during this initial 6 months was 95%; for 5 years of remission, it was 47% as opposed to 75% for 1 year of remission and 24% for 5 years of remission if there had been 10 or more seizures during this period. The number of seizures in the early phase of epilepsy (here, taken as the first 6 months after presentation) is the single most important predictive factor for both early and long-term remission of seizures.
Li R, Zhao D, Li N, Lin W Front Neurol. 2024; 15:1429964.
PMID: 39507625 PMC: 11538064. DOI: 10.3389/fneur.2024.1429964.
An unidentified yet notable modification on and caused by ramelteon.
Wu P, Tu Y, Cho H, Yu M, Wu Y, Wu S FASEB Bioadv. 2024; 6(10):442-453.
PMID: 39372128 PMC: 11452446. DOI: 10.1096/fba.2024-00008.
Kellenaers J, Rijkers K, van Mastrigt G, Schijns O, Hoogland G, Dings J BMJ Open. 2023; 13(7):e064263.
PMID: 37407053 PMC: 10335478. DOI: 10.1136/bmjopen-2022-064263.
Polymorphisms Affecting the Response to Novel Antiepileptic Drugs.
Urzi Brancati V, Pinto Vraca T, Minutoli L, Pallio G Int J Mol Sci. 2023; 24(3).
PMID: 36768858 PMC: 9917302. DOI: 10.3390/ijms24032535.
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt S, Sudell M, Cividini S, Marson A, Tudur Smith C Cochrane Database Syst Rev. 2022; 4:CD011412.
PMID: 35363878 PMC: 8974892. DOI: 10.1002/14651858.CD011412.pub4.